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The Notch signaling pathway is an evolutionarily conserved cell signaling system present in most multicellular organisms, as it
controls cell fate speciﬁcation by regulating cell proliferation, diﬀerentiation, apoptosis, and survival. Regulation of the Notch
signaling pathway can be achieved at multiple levels. Notch proteins are involved in lineage fate decisions in a variety of tissues
in various species. Notch is essential for T lineage cell diﬀerentiation including T versus B and αβ versus γδ lineage speciﬁcation.
In this paper, we discuss Notch signaling in normal T-cell maturation and diﬀerentiation as well as in T-cell acute lymphoblastic
lymphoma/leukemia.
1.Notch SignalingPathway
The Notch gene was initially described in a mutant strain
of fruit ﬂy Drosophila melanogaster with notched wing
blades in 1917 by Morgan [1]. This notched wing phenotype
resulted from a partial loss of function of the Drosophila
Notch gene, which was cloned and characterized in the mid-
1980s [2, 3]. The Notch signaling pathway is an evolution-
arily conserved cell signaling system present in most mul-
ticellular organisms, as it controls cell fate speciﬁcation by
regulating cell proliferation, diﬀerentiation, apoptosis, and
survival [4]. Mammals possess four transmembrane Notch
r e c e p t o r s( N o t c h 1 ,2 ,3 ,a n d4 ) ,[ 5–10] which can interact
with ﬁve Notch ligands (Delta-like 1 (DL1), Delta-like 3
(DL3), Delta-like 4 (DL4), Jagged1 and Jagged2) [11–16].
The Notch receptors are synthesized as single protein which
are proteolytically cleaved in the Golgi by a furin-like pro-
tease at site S1 during transport to the cell surface, resulting
in heterodimers consisting of the extracellular domain and
the transmembrane domain followed by the intracellular
domain of the Notch receptor [17].The extracellulardomain
of Notch contains 29–36 epidermal growth factor- (EGF-)
like repeats (36 in Notch1 and Notch2, 34 in Notch3,
and 29 in Notch4) that are responsible for ligand binding
interactions [18]. The EGF-like repeats are followed by
threecysteine-richLIN12-Notchrepeats(LNRs)thatprevent
ligand-independent activation of Notch signaling pathway
[19, 20] and the heterodimerization domain (HD). The
intracellular domain of Notch contains an RAM23 domain
followed by six ankyrin repeats (ANK) involved in binding
to the CSL transcription factor [21, 22], a transactivation
domain (TAD), and a PEST motif (polypeptide enriched in
proline (P), glutamic acid (E), serine (S), and threonine (T))
that regulates protein stability [23, 24].
Ligand-receptor interaction between neighboring cells
triggers two successive proteolytic cleavages of the receptor,
which release the intracellular portion of the Notch receptor
(ICN) from the plasma membrane. The ﬁrst cleavage is
mediated by ADAM (a disintegrin and metalloprotease)
proteases at site S2, located on the extracellular side, about
12 amino acids away from the transmembranse domain,
which is a key regulatory step in Notch activation [20]. The
second proteolytic cleavage is mediated by the γ-secretase
complex containing presenilin and nicastrin within the
transmembrane domain at site S3. This releases intracellular
domain of Notch which then translocates to the nucleus,
where it binds to the DNA-binding transcriptional factor
CSL [25, 26] (known as CBF1 in human, suppressor of
hairless in Drosophila, LAG in Caenorhabditis elegans,
and also called RBP-Jκ in mice). In the absence of ICN,2 ISRN Hematology
CSL represses transcription by binding to the promoters
of target genes and recruiting histone deacetylases and
corepressors such as SMRT/NcoR and SHARP/MINT/SPEN
[27, 28]. When ICN binds to CSL, it recruits the coactivators
including Mastermind-like1 (MAML1) [29, 30] and histone
acetyltransferase [31], which binds to ICN in the ICN-CSL-
DNA complex, thereby converting the CSL complex into a
transcriptional activator.
2. Modulation of Notch Signaling
Regulation of Notch signaling pathway can be achieved at
multiple levels. First, Fringe proteins have been identiﬁed
as Golgi-localized glycosyltransferases that inhibit Notch
signaling by interfering with Notch receptor-ligand interac-
tions through glycosylation [32–36]. Koch and co-workers
showed that T cell speciﬁc ectopic expression of Lunatic
Fringe decreases T-cells and induces lymphoid progenitor
to adopt the B-cell fate in the thymus [37]. Second, the
γ-secretase inhibitors (GSIs) eﬀectively block activation of
Notch receptor by preventing proteolytic cleavage at site
S3, releasing the Notch intracellular domain (ICN) [38].
It has been shown that treatment of T-ALL cells with
the GSI results in cell cycle arrest followed by apoptosis
[39]. Third, MAMLs are important for Notch-dependent
CSL transcriptional activation [29, 30]. Dominant negative
mutants of MAML are capable of inhibiting Notch signaling
sinceDNMAML1containsonlytheN-terminalICN-binding
basic domain which allows them to bind to ICN but lacks
the activation domain therefore, DNMAML1 antagonizes
Notch1 signaling by inhibiting recruitment of transcription
coactivators [40–42]. Studies from the Pear group show
that expression of DNMAML1 leads to marked inhibition
of early T-cell diﬀerentiation and to the appearance of
intrathymic B cells, phenotypes consistent with inhibition
of Notch1 [43]. Fourth, Fbw7 is the F-box component of
an SCF-E3 ubiquitin ligase complex (SCFFBW7). Fbw7 targets
Notch1 for ubiquitination and degradation [44–46]. The
PEST domain in the C terminus of the Notch1 receptor
is essential for phosphorylation-mediated and proteasome-
dependent degradation of Notch1, because Fryer et al.
reported that CycC:CDK8 phosphorylates the ICN1 within
the TAD and PEST domains, and CycC:CDK8 expression
strongly enhances ICN1 hyperphosphorylation and PEST-
dependent degradation by the Fbw7 in vivo [47], suggesting
that Notch1 protein stability could be a critical regulator of
intracellular signaling thresholds.
3.NotchinT-CellDevelopment
3.1. T versus B Lineage. Notch proteins are involved in
lineage fate decisions in a variety of tissues in various species
[4]. Notch is essential for T lineage cell diﬀerentiation. Loss-
of-function experiments have shown that Notch plays a
crucial role in determining T lymphoid versus B lymphoid
lineage decision [48–50]. Conditional deletion of Notch1 in
hematopoietic progenitors induces a block of early T-cell
development and accumulation of ectopic immature B-cells
in the thymus [49, 50]. Similar phenotype was observed in
the mice harboring Cre-mediated deletion of RBP-J created
by Han et al. [48]. Moreover, interference with Notch
receptor-ligandinteractionsorinhibitionofNotch-mediated
transcriptionresultsinfailureofTcelldevelopmentandpro-
motion of B cell development [37, 43]. Conversely, gain-of-
function analyses involving overexpression of constitutively
active Notch1 in bone marrow lineage negative progenitors
indicate that activated Notch1 results in thymic-independent
T-cell development at the expense of B-cell development in
the BM and does not inﬂuence granulocyte maturation [51].
Nevertheless, other studies suggest that constitutive Notch1
activity blocks or delays myeloid diﬀerentiation concomitant
with ectopic T-cell development [52–55]. Thus, whether or
not activated Notch1 aﬀects myeloid diﬀerentiation remains
controversial. Taken together, these ﬁndings demonstrate
that Notch1 singaling is essential to induce T-cell lineage
commitment from the multipotent hematopoietic progeni-
tor cells (HPCs).
3.2. Early T-Cell Development. The earliest intrathymic T-
cellprecursors,ETPs,whicharecharacterizedbyhighexpres-
sion of c-Kit receptor and low expression of the interleukin
7 receptor alpha chain (IL7R), are found in the double-
negativeDN1thymocytesubset(CD4−CD8−CD25−CD44−)
[56–59]. Notch signaling is required not only for generation
of the ETP population but also for transitions of ETP-to-
DN2 and ETP-to-DN3 suggesting that Notch1 activation is
needed continuously to promote survival or proliferation
throughout the early stages of intrathymic T-cell develop-
ment [58, 59]. Consistent with these ﬁndings, a number
of in vitro studies provide supportive evidences showing
that Notch receptor-ligand interactions are necessary for
induction and maintenance of T-cell lineage speciﬁcation at
both the DN1 and DN2 stages of T-cell development [60,
61] and that enforced expression of Notch inhibitor Nrarp
(Notch-regulated ankyrin-repeat protein) in mouse HSCs
results in a profound block during progression through early
stages of thymocyte maturation (DN1–DN3) [62].
3.3. β-Selection Checkpoint. There are two checkpoints
during T-cell development, where cells are rescued from
programmed cell death and progress in their develop-
ment [63, 64]. Commitment to either the CD4+CD8+αβ
or CD4−CD8−γδ lineage occurs at the ﬁrst checkpoint
[65]. DN3 cells that generate the productive TCR-β chain
rearrangement which can be assembled into the pre-T-cell
receptor (pre-TCR) complex consisting of a TCRβ chain, the
invariant pTα chain [66], and CD3 molecules can survive
the transition from DN3 to DN4, this process is termed β
selection [67–69]. Loss of RAG-1 or RAG-2 in vivo results
in total inability to initiate V(D)J rearrangement, leading
to the arrest of developing αβ lineage thymocytes at the
DN3 stage [70, 71]. At the second checkpoint in T-cell
development, cells on the αβ lineage are rescued from cell
death by binding of their αβ TCR to thymic MHC molecules,
allowing CD4+CD8+ thymocytes to undergo positive and
negative selection [63, 64]. Wolfer and colleagues reported
that inactivation of Notch1 prior to the DN3 stage severely
impairs αβ but not γδ T-cell development and partiallyISRN Hematology 3
blocks thymocyte development at the pre-TCR checkpoint
due to a severe impairment of Vβ-DJβ rearrangement [72].
Conditional ablation of the gene encoding RBP-J at an
earlier developmental stage results in enhanced generation
and accelerated emigration of γδ T cells, whereas αβ T-cell
development is arrested at the DN3 stage [73]. Inhibition
of Notch signaling by DNMAML in DN3 stage leads to
similar consequences [40]. Moreover, the OP9-DL1 in vitro
T-cell diﬀerentiation system provides an ideal system to
mimic in vivo T-cell development established by Z´ u˜ niga-
Pﬂ¨ ucker and colleagues [74, 75]. They made use of OP9-DL1
system to demonstrate that pre-TCR signaling concurrent
with Notch receptor-ligand interactions are required for
productive β selection outcomes including rescue from
apoptosis, proliferation, and transition of DN thymocytes to
the DP stage of T-cell development [76–78].
3.4. αβ versus γδ Lineage. In vitro experiments provided
evidence that bifurcation of the αβ and γδ T-cell lineages
is completed at the DN3 stage [77, 79–82]. Robey and
colleagues examined the eﬀe c to fN o t c ha c t i v i t ya n dt h e
T-cell receptor in the αβ versus γδ T-cell lineage choice.
They showed that cells with Notch+/− g e n ea r el e s sl i k e l y
to become αβ T-cells than wild type cells with Notch+/+
gene that develop in the same mouse. In addition, they also
providedevidencethatγδtoαβTcellsareconsistentlyhigher
inTcellsderivedfromNotch+/− stemcellscomparedtowild-
type cells, implying that reduced Notch activity favors the
γδ lineage over the αβ lineage. We have shown that γδTCR-
expressing cells can survive and expand in the absence Notch
signals [83]. Mice deﬁcient in Jagged2 exhibit altered thymic
morphology and impaired diﬀerentiation of γδ lineage T
cells [84], suggesting that Jagged2-mediated Notch signaling
participates in γδ lineage diﬀerentiation. However, the role
of Notch signals during αβ versus γδ T lineage decision
remains controversial. Experiments by Wolfer and colleagues
demonstrate that conditional deletion of Notch1 signaling at
DN2-DN3 developmental stage leads to severe perturbation
of αβ but not γδ lineage development [72]. In fact, Garbe
et al. [83] a sw e l la sC i o f a n ie ta l .[ 77] demonstrated a stage-
speciﬁc requirement for Notch signaling at the αβ and γδ T
lineage bifurcation.
4.Notch SignalinginT-ALL
The involvement of Notch1 was ﬁrst observed in the
t(7;9)(q34;34.3)translocation,ararerecurrentchromosomal
rearrangement present in <1% of human T-ALL patients.
Thet(7;9)(q34;34.3)translocationjuxtaposestheC-terminal
region of EGF repeat 34 of the human NOTCH1 gene
next to the TCRβ promoter/enhancer, resulting in the
activated expression of NOTCH1, which was named TAN1
for translocation-associated Notch homolog [5]. TAN1 was
shown to function as a speciﬁc oncoprotein for T cells in
themurinebonemarrowtransplantationmodel.Themurine
tumors induced by TAN1 in this model are phenotypi-
cally similar to the TAN1-associated human tumors [85].
Notch was originally thought to play a minor role in the
molecular pathogenesis of human T-ALL due to the rare
frequency of t(7;9)(q34;34.3) translocation involving Notch
in human T-ALL cases. More recently, it was shown that
more than 50% of human T-ALLs, including tumors from all
major molecular oncogenic subtypes, have gain-of-function
mutations that involve the extracellular heterodimerization
domain and/or the C-terminal PEST domain of NOTCH1
[86]. Following this ﬁnding, activating mutations of Notch1
as well as mutants of genes that regulate turnover of
intracellular Notch1 have been detected in mouse models
of T-ALL [44, 45, 87–89]. Thus, these studies have sparked
renewed interest in the pathogenesis of T-ALL and greatly
expanded the role of NOTCH1 in the etiology and molecular
tumorigenesis of this human disease with the hope of
ﬁnding novel targeted therapies that interfere with NOTCH
signaling.
4.1. E2A Inhibition. E-proteins are members of highly con-
served basic helix-loop-helix (bHLH) family of transcription
factors which plays a critical role in cellular diﬀerentiation.
The E2A gene encodes two alternatively spliced transcripts
which produce two proteins, E47 and E12 [90–92]. These
proteins bind as homo- or heterodimers with other basic
helix-loop-helix proteins as transcription factors to E-box
consensus sequences and have an essential function in B-
cell and T-cell development [93, 94]. E2A-deﬁcient mice lack
B cells and regularly develop T-ALL [95]. Notch inhibition
of E47 was initially described by Ordentlich et al. [96]
who demonstrated that Notch and Notch downstream target
Deltex act on E2A-encoded E47 by inhibiting signaling
through Ras. Two mechanisms of E2A inhibition by Notch
havebeenreported:Notch-mediatedupregulationofthepre-
TCR signaling leads to ERK-MAPK-dependent upregulation
of the E2A inhibitors Id1 or Id3 which prevent binding of
E2A-encodedproteinstoE-boxmotifs[93,97].Alternatively,
overexpression of Notch induces E2A protein degradation
through ubiquitination-proteasome-mediated pathway both
in vitro and in vivo [98, 99]. Most T-ALLs induced by
other oncoproteins such as TAL1, LMO1, or LMO2 are
characterized by inhibition of the transcriptional activity of
the E2A proteins [100–105], suggesting that E2A could be
an essential pathway in the leukemogenesis of T-ALL. In
order to evaluate the role of E2A-encoded E47 protein as
a potential tumor suppressor in murine T-ALL, we have
introduced nondegradable mutant E47 by retroviral vector
intointracellulardomainofNotch1-(ICN1-)overexpressing
tumors, and we found that overexpression of E47 led to
suppression of tumor cell growth [98]. Taken together, these
ﬁndings suggest that E2A may function as tumor suppressor,
and inhibition of E2A activity is a common and critical event
in the pathogenesis of T-cell lymphoma.
4.2. c-Myc Activation. The c-Myc proto-oncogene is a basic
helix-loop-helixleucinezipper(b/HLH/LZ)proteininvolved
in cellular growth and diﬀerentiation. c-Myc has been iden-
tiﬁed as a critical direct downstream target gene of NOTCH1
inleukemogenesis[89,106,107].Inhibitorsofc-Mycprevent
Notch1 from rescuing T-ALL cells treated with γ-secretase
inhibitor (GSI), and overexpression of c-Myc is suﬃcient
to rescue most human T-ALL cell lines from GSI-induced4 ISRN Hematology
growth arrest [107]. Palomero and co-workers showed
that Notch1 controls a feed-forward-loop transcriptional
network that regulates cell growth and proliferation and that
Notch1 directly activates multiple biosynthetic routes and
targets c-Myc using integrating gene expression array and
ChIP-on-ChIP analysis [106]. Sharma and colleagues devel-
oped doxycycline- (Dox-) regulated Notch1-IC mouse T-
ALL cell lines and identiﬁed c-Myc as a direct Notch1 target
gene in Notch1-induced T-ALL transformation using gene
expression proﬁling and chromatin immunoprecipitation
(ChIP) analysis in this cell line [89]. Moreover, Notch1 inhi-
bition leads to cell cycle arrest and decreases c-Myc mRNA
levels [89]. The results are consistent with those in human T-
ALL studies [106, 107], implying that the direct activation of
c-Myc mediated by Notch1 is required to maintain leukemic
growth.ToevaluatethemechanismbywhichNotch1directly
targets c-Myc, Satoh et al. [108] have demonstrated that
activated forms of Notch1 and its downstream eﬀector CSL
can bind to the responsive element (TTCCCAA) located
between −195bp and −11bp of the c-Myc promoter by
luciferase reporter assay and electrophoretic mobility shift
assay (EMSA). The recruitment of Notch1 to the CSL-
binding sites in the c-Myc promoter has been conﬁrmed by
other investigators [89, 106, 107, 109]b yl u c i f e r a s er e p o r t e r
assay, EMSA, or chromatin immuno-precipitation (ChIP)
analysis. We have previously systematically investigated
oncogenesis of T-ALL initiated by ICN1 overexpression in a
bone marrow transplantation (BMT) model; we found that
c-Myc is upregulated in nonmalignant ICN1-overexpressing
cells as well as malignant ICN1-overexpressing cells at both
of mRNA and protein levels [98]. Furthermore, we have
shown that deletion of c-Myc at the CD4+CD8+ stage of
T cell development prevented tumor formation induced
by Notch1 [98]. Girard and colleagues performed provirus
insertional mutagenesis in c-Myc transgenic mice to identify
c-Myc collaborators in leukemogenesis; they observed that
Notch1 was mutated by provirus insertion upstream of the
exon coding for the transmembrane domain of Notch1,
resulting in high expression of truncated Notch1 RNAs and
proteins [110]. Moreover, in collaboration with the Look
lab, we have reported that dysregulated Myc expression
is shared between ICN1-induced murine model and most
human T-ALLs with Notch1 gene mutations [111]. These
results suggest a collaboration of c-Myc and Notch1 in
oncogenesis.
4.3. Cell Cycle Progression. Cell cycle progression is regulated
at several checkpoints of cellular process. Notch signaling
has been shown to be a potent regulator of cell cycle
progression in T-ALL cells [86, 89, 112]. Sicinski and
colleagues [113] have studied the function of cyclin D3
in T-cell development and T-cell leukemogenesis, and they
found that cyclin D3−/−) mice show impaired expansion of
immature T lymphocytes, characterized by a marked deﬁcit
of CD4+CD8+ T cells. Cyclin D3 deﬁciency inhibits T-ALL
induced by Notch1, suggesting the requirement of cyclin D3
for the growth of T-ALL tumors derived from immature T
cells. To evaluate the mechanism by which Notch1 regulates
cell-cycle progression in T-ALL, experiments from Joshi
group [114] show that cyclin D3 functions together with
its catalytic partners CDK4 and CDK6 to facilitate cell
cycle progression in Notch1-dependent T-cell lymphoma,
because Notch1 binds directly to the region of −1764bp to
−1537bp of cyclin D3 promoter and speciﬁcally regulates
cyclin D3 promoter activity revealed by ChIP analysis and
luciferase reporter assay. Inhibition of Notch activation with
GSI treatment abrogates the occupancy of Ntoch1 to the
cyclin D3 promoter, suggesting that cyclin D3 is a direct
target of the Notch/CSL signaling pathway [114]. While
cyclin D3 expression contributes to cell-cycle progression in
Notch-mediated human T-ALL cell lines, overexprssion of
CDK4 or CDK6 together with cyclin D3 partially rescues
these cell lines from GSI-induced G1 arrest. Moreover, cyclin
D3 and CDK4 are highly expressed in Notch-dependent
leukemic mice [114], which is consistent with our previous
report [98]. Cyclin-dependent kinases (CDKs) and cyclin-
dependent kinase inhibitors (CKIs) play important roles in
the regulation of G1/S phase transition [115]. Sarmento
[116] and colleagues provided the ﬁrst evidence that Notch
signaling links to the F-box protein SKP2, which is the sub-
unit of the E3-ubiquitin ligase SCFSKP2 that degrades p27Kip1
andp21Cip1.TheirdatashowedthatNotchsignaling pathway
speciﬁcally degrades p27Kip1 and p21Cip1 by directly inducing
CSL-dependent transcription of SKP2, which subsequently
enhances CDK2 kinase activity and accelerates cell cycle
entry into S phase. Depletion of SKP2 by siRNA in G1 phase
stabilizes p27Kip1 and p21Cip1, abolishes Notch eﬀect on G1-S
progression, and results in a signiﬁcant reduction of cells in S
phase [116]. This is consistent with observations from other
groups demonstrating that GSI inhibition of Notch signaling
in human T-ALL cell lines results in G0/G1 cell cycle arrest
by downregulation of SKP2, upregulation of p27Kip1,a n d
derepression of RB [117, 118].
4.4. ARF-Mdm2-p53 Pathway. The ARF-Mdm2-p53 tumor
surveillance pathway is important for Myc-mediated apop-
tosis in primary mouse embryoﬁbroblasts (MEFs) [119],
whereas this pathway is frequently inactivated in Myc-
induced lymphoma in vivo [120]. To evaluate whether or
notc-myc-ARF-Mdm2-p53axisisintactinICN1-dependent
tumor cells, we have shown that p53 and p19arf were down-
regulated and Mdm2 was upregulated at both mRNA and
protein levels in the tumor cells compared with nontumori-
genic ICN1-overexpressing cells [98]. This study indicates
that dysregulation of the c-Myc-p53 axis occurs in the face
of genomic stability as revealed by spectral karyotype (SKY)
and array-base comparative genomic hybridization (aCGH).
Consistent with these observations, the Beverly group [121]
reported that Notch suppresses p53 in lymphomagenesis in
Notch1transgenicmice,andp53isactivateduponinhibition
of Notch signaling by GSI. They further proposed that Notch
suppresses p53 in lymphomagenesis through repression of
the ARF-Mdm2-p53 pathway.
4.5. PTEN/PI3K/Akt-mTOR Pathway. To identify novel pro-
oncogenic pathways regulated by Notch, Chan et al. [122]
used reverse phase protein (RPP) microarrays to proﬁle the
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proteins in 13 T-ALL cell lines treated with GSI they found
that the phosphorylation of multiple signaling proteins in
the mTOR pathway was suppressed by inhibition of Notch
signalinginaNotch-dependentmanner,asthisphenomenon
can be rescued by expression of ICN1 and mimicked by
dominant negative MAML1, suggesting that Notch signals
positively regulate activity of the mTOR pathway in T-ALL.
More importantly, the eﬀect of GSI on the mTOR pathway
can also be rescued by c-Myc because c-Myc is a direct
transcriptional target of Notch. Inhibition of mTOR by
rapamycin combined with GSI treatment synergistically
inhibited T-ALL cell growth [122]. Consistently, the work
from other group showed that Notch1 signaling confers
chemoresistance in a wild-type p53-dependent manner.
Notch inhibited p53 through the PI3K-Akt/protein kinase B-
(PKB-) mammalian target of rapamycin (mTOR) pathway,
and the inhibition of this pathway reversed the chemore-
sistance [123]. PTEN, a tumor suppressor which negatively
regulates PI3-kinase-Akt signaling pathway, is consistently
downregulated in GSI-resistant T-ALL cell lines [124]. The
Palomero group found that transcriptional downregulation
of PTEN mediates physiologic upregulation of the PI3K-
AKT pathway; mutational loss of PTEN and aberrant Akt
activation induce resistance to GSI in T-cell leukemia [124].
In contrast to these ﬁndings, Medyouf et al. [125]r e p o r t e d
that T-ALLs remain dependent on Notch signaling and
found no correlation between PTEN status and resistance
to Notch inhibition in primary human T-ALL and mouse
model of T-ALL.
5. Conclusions andPerspectives
Large numbers of work over the last decade have demon-
strated that Notch signaling is essential for T-cell lineage
fate decision, and aberrant activation of Notch signaling
plays a critical role in etiology and pathogenesis of T-cell
acute lymphoblastic Lymphoma/Leukemia. Activated Notch
signaling is required for the transformation and growth
of T-cell lymphoma/leukemia; downstream pathways that
transmit pro-oncogenic signaling are poorly understood. In
the mouse model, Notch1-mediated T-ALL develops mon-
oclonal tumor; thus, another unknown secondary genetic
event needs to be elucidated. Altered expression of miRNAs
has been involved in various types of cancers including
hematopoietic malignancies; however, the role of miRNAs
in T-cell development and T-ALL tumorigenesis is not
well characterized, although few related studies have been
reported [126–128]. In the future, combination of GSI and
downstream pathway regulators such as mTOR inhibitor
or CyclinD3 inhibitor will represent a novel approach for
treating this aggressive human malignancy.
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